Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Will Enforce NDI Notification Requirement Without Warning

This article was originally published in The Tan Sheet

Executive Summary

FDA likely will not issue warnings before taking judicial actions against firms that fail to comply with the new dietary ingredient notification regulation once the agency publishes a long-awaited guidance

Related Content

NDI Notification Enforcement Ramp-Up Likely To Target “Low-Hanging Fruit”
Low NDI Notice Compliance Sets Stage For Enforcement – FDA’s Fabricant
Better Intra-Agency Reviews Could Speed FDA Seizure, Injunction Decisions
NDI Needed In Absence Of "Concrete Evidence" Of Prior Sale – Attorney
FDA Oversight Among Hot Button Issues In 112th Congress
"Insufficient Data" Linked To Most NDI Notification Failures At FDA
CHPA Manufacturing Controls Seminar In Brief
FDA Enters New Enforcement Territory With Warnings Against Failed NDIs
Supplement Firms Must Calculate Risk From Claims To Survive - Attorneys
Harkin, Hatch Reload In Hunt For Full DSHEA Funding, Implementation





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts